# Payers fund trials of cheaper, shorter or lower-dose versions of expensive treatments

Source: https://onco.cc/ideas/idea-fund-payer-funded-pragmatic-trials/  
OnCo record `idea-fund-payer-funded-pragmatic-trials` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Health insurers and national health systems have every reason to find out whether half the dose or half the duration of a costly drug works as well. They would fund those trials directly and keep the savings.

## Summary

Payers commission pragmatic randomised trials of dose reduction, shorter duration, extended dosing intervals, stopping rules and cheaper alternatives for high-cost oncology drugs, embedded in routine care with registry endpoints. No manufacturer will run these; academic groups lack money. Precedents include the UK's REFINE-Lung (reduced-frequency pembrolizumab), the Netherlands' payer-supported trials of lower-dose abiraterone and dose-reduced ibrutinib, and the Dutch SONIA trial on CDK4/6 sequencing, whose savings dwarfed its cost. A standing payer trials fund with a savings-reinvestment rule would make this systematic.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A payer trials fund of $50 million a year yields treatment-modification results whose first-year savings exceed the fund's total cost, without loss of efficacy in non-inferiority designs, for at least two of the first five trials.
- Rationale: SONIA showed that deferring CDK4/6 inhibitors saved months of toxicity and large costs with no survival difference; dose-optimisation trials of abiraterone with food and of ibrutinib have shown equivalence at a fraction of the dose. Payer-funded research is standard in some countries (ZonMw in the Netherlands, NIHR HTA in the UK) but rare in oncology elsewhere.
- Proposed test: Establish the fund in one system, run five pragmatic trials with pre-specified savings estimates, and audit realised savings versus fund cost after four years.
- Maturity: early-clinical
- Actor: payer

## Sources

- FDA Project Optimus: https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus

## Connected records

- ideas: [A fixed share of trial-group funding for getting proven care to patients](https://onco.cc/ideas/idea-fund-implementation-quota/), [A trials fund reserved for older and multimorbid patients](https://onco.cc/ideas/idea-fund-older-patients-trial-fund/), [Extra exclusivity for sponsors who run treatment-duration and de-escalation trials](https://onco.cc/ideas/idea-fund-duration-trial-exclusivity/), [Pay per course of radiotherapy, not per session, so short courses are not penalised](https://onco.cc/ideas/idea-fund-course-based-radiotherapy-payment/), [Payer-funded trials that omit surgery or radiotherapy in low-risk patients](https://onco.cc/ideas/idea-fund-omission-deescalation-trials/)
- drugs: [Palbociclib](https://onco.cc/drugs/palbociclib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Ribociclib](https://onco.cc/drugs/ribociclib/)
- institutions: [Netherlands Cancer Institute (NKI-AvL)](https://onco.cc/institutions/nki/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/), [Wrong doses](https://onco.cc/bottlenecks/b-dose-optimisation/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-payer-funded-pragmatic-trials.json